Clinical trial · Interventional
TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris
A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of TSN2898 Topical Gel for the Treatment of Acne Vulgaris
NCT02796066CI-TRIAL-00027205withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Protocol not approved
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety and effectiveness of TSN 2898 topical gel in the treatment of moderate to severe acne.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acne Vulgaris | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TSN2898 | Drug | — | UNRESOLVED |
| Vehicle | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- PLACEBO_COMPARATOR
- label
- Vehicle
- description
- Vehicle gel
- interventionNames
- Drug: Vehicle
- type
- EXPERIMENTAL
- label
- Low Dose Active
- description
- Low Dose of TSN2898
- interventionNames
- Drug: TSN2898
- type
- EXPERIMENTAL
- label
- Mid Dose Active
- description
- Mid Dose of TSN2898
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Healthy males or females, 16 to 55 years of age * Must be diagnosed as having moderate or severe acne vulgaris * ≥ 20 inflammatory lesions on the face * ≥ 20 non-inflammatory lesions on the face * ≤ 3 nodule/cyst acne lesions * Medically healthy * Females must be of non-childbearing potential Exclusion Criteria: * Systemic therapy with retinoids within six (6) months prior to study start * Topical use of prescription retinoids within four (4) weeks prior to study start * Oral antibiotics within four (4) weeks prior to study start * Topical dapsone, sulfacetamide, benzoyl peroxide, α-hydroxy/glycolic acid and retinol/retinaldehyde-containing products, and topical antibiotics, anti-inflammatory medications and corticosteroids on the face within two (2) weeks prior to study start * Facial procedures, including lasers, peels, and dermabrasion, within two (2) months prior to study start
References
Publications (0)
Data not yet available
No reference posted for this study.